Xencor Inc. Stock
Price
Target price
€6.30
€6.30
0.000%
-
0.000%
€27.91
22.08.25 / Stuttgart Stock Exchange
WKN: A1W96L / Symbol: XNCR / Name: Xencor / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Xencor Inc. Stock
There is no change in the price for Xencor Inc. today.
We see a rather positive sentiment for Xencor Inc. with 12 Buy predictions and 1 Sell predictions.
Based on the current price of 6.3 € the target price of 27 € shows a potential of 328.57% for Xencor Inc. which would more than double the current price.
Pros and Cons of Xencor Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Cons
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xencor Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xencor Inc. | 0.000% | -3.077% | -18.710% | -57.143% | -72.368% | -78.276% | -78.716% |
| Ironwood Pharmaceuticals | 8.020% | 10.989% | 51.880% | -76.066% | -75.952% | -91.251% | -88.588% |
| Novocure Ltd | 2.000% | 5.888% | -23.532% | -32.549% | -63.565% | -86.494% | -84.083% |
| Iovance Biotherapeutics Inc. | 4.150% | 5.333% | -14.403% | -78.108% | -66.826% | -80.657% | -90.695% |
Comments
Xencor (NASDAQ:XNCR) had its price target lowered by analysts at Royal Bank Of Canada from $32.00 to $15.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor, Inc. (NASDAQ: XNCR) had its price target lowered by analysts at Wells Fargo & Company from $33.00 to $27.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor, Inc. (NASDAQ: XNCR) had its price target lowered by analysts at Wedbush from $31.00 to $26.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
News
Xencor (XNCR) Q2 Revenue Jumps 82%
Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered antibodies for serious diseases, reported second quarter 2025 results on August 6, 2025. The company’s GAAP
Xencor Reports First Quarter 2025 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results